07:57 AM EDT, 06/18/2025 (MT Newswires) -- AbbVie ( ABBV ) said Wednesday its phase 3 study of atogepant in migraine prevention for adults achieved its primary and all six secondary endpoints.

The company said the trial met its primary endpoint of atogepant leading to fewer treatment discontinuations linked with adverse events compared with topiramate.

The secondary endpoints include a significant reduction in mean monthly migraine days, exhibiting clinical efficacy, AbbVie ( ABBV ) added.

Atogepant's safety profile in the study was "generally consistent" with that from prior studies, according to the company.